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Response to Belalcazar and Swank
W e read Belalcazar and Swank’s re-sponse (1) to our article withgreat interest. They have valid
concerns regarding potentially biased esti-
mates of treatment effects in small transla-
tional research studies where circumstances
and environments are not as easily con-
trolled as they are in efficacy-based re-
search (2).
Our study (3) was a pilot, random-
ized, controlled trial of a multifaceted di-
abetes care intervention. Eleven primary
care practices and their patients (n 
762), all from the same underserved com-
munity, were block randomized to one of
three study groups before the start of the
intervention. Practices were randomized
instead of individual patients to ensure
consistent delivery of the intervention for
all patients and to eliminate contamina-
tion of the intervention between patients
in the same practice (4).
Given the small number of practices
randomized and the small sample of pa-
tients evaluated, the authors are correct
that the study groups may be imbalanced
with respect to several factors, even when
the P values, which depend on sample
size, are not statistically significant. To ad-
dress this concern, we identified the most
important and best “fitting” covariates
(age, insulin, baseline metabolic value,
study group, and the nesting of practices
within study group) with a series of ana-
lytical techniques and a review of the lit-
erature and then adjusted for these
variables when analyzing differences be-
tween study groups. We acknowledge the
authors’ suggestion about adjusting for
ethnicity; however, with 10 nonwhite
subjects in the study, this was not feasible.
Despite the small sample size, statistically
significant differences between study
groups were observed, lending further
credence to our results.
The authors suggest using propensity
scores to correct for differences in base-
line characteristics among study groups
(4). In observational studies, in which the
selection of an intervention (e.g., insulin
use) depends on various patient factors,
using a propensity score, the estimated
probability of receiving one of the inter-
ventions based on the patient-specific fac-
tors, can greatly reduce selection bias. As
our study was a randomized controlled
trial, we do not have variables that are
truly related to the probability of receiv-
ing a particular intervention, since the in-
terventions were randomly assigned a
priori. Thus, a propensity score cannot be
applied to this study. It may be possible to
create an alternative composite score that
would encompass several risk factors in fu-
ture analyses of these types of interventions.
Variations on the multifaceted diabe-
tes care intervention described in our ar-
ticle are currently being studied in a
variety of settings, both locally and na-
tionwide. Unfortunately, the majority of
these efforts suffer from small sample size
and a lack of randomization (5). In these
studies, the use of propensity scores may
enhance the validity of the results.
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Response to De Block et al.
I read with interest the article by DeBlock et al. (1). Indeed, reliable devicesrecording continuously interstitial glu-
cose concentrations (IGCs) may be an al-
ternative to frequent glucose monitoring,
especially in patients of intensive care
units (ICUs) in whom normoglycemia has
become a major target. However, all fac-
tors influencing the complex kinetics of
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IGCs should be understood before con-
sidering continuous glucose monitoring
(CGM) as a valuable and accurate alterna-
tive to track hyperglycemia and adapt in-
sulin therapy. In addition, to use CGM in
an optimal way, the device should pro-
vide real-time glucose concentrations in
order to quickly adjust insulin infusion
rates according to ambient glucose levels.
This requires initial rather than post hoc
calibration. These two key issues deserve
further comment.
First, the 3-min lag time between
subcutaneous and arterial blood glucose
concentrations emphasized by the au-
thors might be questionable in ICU pa-
tients. Indeed, such lag time depends on
physiological parameters responsible for
a different glucose kinetic between inter-
stitium and plasma (2). Such kinetic dif-
ference has been shown to lead to
spurious hypoglycemia in the general di-
abetic population (3). Most importantly,
in critically ill patients, the kinetics of IGC
may be affected by alterations in hydric/
ionic balance, as revealed by the presence
of a third compartment and subcutaneous
edema and probably by many other fac-
tors that are still unknown.
Second, the good accuracy of CGM
was not assessed when using the device
GlucoDay in its most optimal manner. In-
deed, real-time glucose levels ideally
should be obtained to adjust insulin ther-
apy as rapidly as possible. This objective
could only be achieved if the GlucoDay is
calibrated 2 h after insertion of the micro-
fiber in the subcutaneous tissue, provided
that glucose levels are stable enough. De
Block et al. used post hoc calibrations
with two or six points. Accuracy was con-
sidered as excellent and, as expected, bet-
ter with the option of more frequent
calibrations (4). However, as all calibra-
tions were performed a posteriori taking
into account all points together, results of
accuracy might be overoptimistic.
Whether the results would be as good
when using CGM to obtain real-time glu-
cose values, i.e., using a single calibration
after 2 h (as recommended by the manu-
facturer) and adjusting progressively
thereafter thanks to later calibrations, re-
mains an open question.
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Belgium.
Address correspondence to Regis P. Rader-
mecker, MD, CHU Sart-tilman, Diabetes, Nutrition,
& Metabolic Disorders, Bat B35 Liège B-4000, Bel-
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W e agree with Dr. Radermecker’s(1) concerns regarding the appli-cability/accuracy of real-time
continuous glucose monitoring (CGM)
for adjusting insulin therapy in the inten-
sive care unit (ICU). This was, however,
not our aim, which was to document the
duration/intensity of unacceptable glyce-
mia in ICU patients (2). For this purpose,
we used the best available method—a
posteriori calibration. Since we observed
that insulin therapy based on discontinu-
ous glucose measurements failed to main-
tain normoglycemia, we suggested that it
might be improved using online CGM.
Regarding the lag time between blood
and interstitial fluid glucose, we acknowl-
edge that both physiological parameters
(equilibration of glucose across the capil-
lary endothelial barrier) and device spe-
cifics (sampling frequency, microdialysis
perfusion rate) should be considered (3).
In a recent study, the delay between blood
and glucose sensed by the GlucoDay was
7 min and mainly explained by instru-
ment delay (6 min) (4). The lag time is
consistent, irrespective of increments/
decrements in glycemia and insulin levels
(3). The hemodynamic alterations we en-
countered (hypotension, shock, vaso-
pressor/inotropic need) did not worsen
error grid analysis results (2). Such vari-
ables would rather affect subcutaneous
glucose recovery/microdialysis, resulting
in a calibration issue, rather than in a sen-
sor performance issue. A lag time of 10
min is clinically acceptable, since online
adjustment of insulin dose should be
based on immediate detection by CGM of
unacceptable rates of change (25 mg 
dl	1  h	1).
Criteria for evaluation of CGM perfor-
mance and calibration are urgently
needed. CGM accuracy improved after 6-
instead of 2-point calibration (2). Calibra-
tion should be performed in times of glu-
cose stability (10% change over 9 min),
a paradigm used in the GlucoDay. From
our preliminary results, it seems that for
real-time CGM, a single calibration after
2 h is not satisfactory and that verification
using conventional glucose measure-
ments is still mandatory. Whether pro-
g re s s i ve ad jus tment us ing l a t e r
calibrations improves accuracy needs fur-
ther investigation.
The use of continuous glucose–error
grid analysis to evaluate clinical accuracy
of CGM systems for ICU patients use is
open for discussion (4) and might need
adjustment. Insulin therapy in the ICU
aims to titrate glycemia in a tight range
(80–110 mg/dl), and changes of 25 mg
 dl	1  h	1 (0.4 mg  dl	1  min	1) al-
ready require a change in insulin dose (5).
The currently used boundaries of 1 mg 
dl	1  min	1 are therefore not rigorous
enough.
Hopefully these observations will
stimulate a debate on current glycemic
monitoring, the choice of dynamic
boundaries for rate–error grid analysis,
the need for standard methods to assess
accuracy, and the definition of valid re-
quirements for CGM systems in the ICU.
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